 | Up a level |
Hatton, Matthew QF, Lawless, Claire Anne, Faivre-Finn, Corinne, Landau, David, Lester, Jason F, Fenwick, John, Simoes, Rita, McCartney, Elaine, Boyd, Kathleen Anne, Haswell, Tom et al (show 2 more authors)
(2019)
Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
BMJ OPEN, 9 (1).
e019903-.
Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J 
ORCID: 0000-0001-5608-001X et al (show 12 more authors)
(2022)
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PloS one, 17 (6).
e0269192-e0269192.
Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy et al (show 11 more authors)
(2021)
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
LANCET ONCOLOGY, 22 (11).
pp. 1530-1540.